MTI had developed a groundbreaking innovation in diagnostics—a novel technology based on "metabolomics" (emerging science). While the science was revolutionary, explaining it to a diverse audience was a significant hurdle.
The company needed to take a complex, data-heavy scientific concept and translate it into a clear, compelling narrative for a product launch. They needed to bridge the gap between the R&D lab and the marketplace, ensuring that everyone—from investors to end-users—understood the value immediately.
1. Strategic Segmentation (Intention) . We couldn't use a "one size fits all" message. I developed a comprehensive Plan of Action that segmented the market into four distinct audiences: Patients, Healthcare Professionals, Laboratories, and Health Regions.
2. Visual Brand Identity (Creativity) To make the abstract science feel tangible, I led a visual overhaul. This involved moving away from dense data toward a clean, accessible brand aesthetic.
3. The Go-to-Market Launch (Connection) The strategy culminated in the product launch for PolypDx™ at a major national nurse mendical conference (SGNA).
By translating complex R&D into a clear, user-friendly brand, MTI was able to successfully launch their flagship product. We moved beyond "explaining the science" to telling a story, creating a communication dashboard that allowed the company to connect with stakeholders across the industry.
Catherine Finlayson Portfolio 2026
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.